1. Biochemistry and Chemical Biology
  2. Neuroscience

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

  1. M Catarina Silva
  2. Fleur M Ferguson
  3. Quan Cai
  4. Katherine A Donovan
  5. Ghata Nandi
  6. Debasis Patnaik
  7. Tinghu Zhang
  8. Hai-Tsang Huang
  9. Diane E Lucente
  10. Bradford C Dickerson
  11. Timothy J Mitchison
  12. Eric S Fischer
  13. Nathanael S Gray  Is a corresponding author
  14. Stephen J Haggarty  Is a corresponding author
  1. Massachusetts General Hospital, Harvard Medical School, United States
  2. Dana-Farber Cancer Institute, United States
  3. Harvard Medical School, United States
https://doi.org/10.7554/eLife.45457
Share this article
Cite this article
  1. M Catarina Silva
  2. Fleur M Ferguson
  3. Quan Cai
  4. Katherine A Donovan
  5. Ghata Nandi
  6. Debasis Patnaik
  7. Tinghu Zhang
  8. Hai-Tsang Huang
  9. Diane E Lucente
  10. Bradford C Dickerson
  11. Timothy J Mitchison
  12. Eric S Fischer
  13. Nathanael S Gray
  14. Stephen J Haggarty
(2019)
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
eLife 8:e45457.
https://doi.org/10.7554/eLife.45457
  2. Download BibTeX
  3. Download .RIS

Abstract

Tauopathies are neurodegenerative diseases characterized by aberrant forms of tau protein accumulation leading to neuronal death in focal brain areas. Positron emission tomography (PET) tracers that bind to pathological tau are used in diagnosis, but there are no current therapies to eliminate these tau species. We employed targeted protein degradation technology to convert a tau PET-probe into a functional degrader of pathogenic tau. The hetero-bifunctional molecule QC-01-175 was designed to engage both tau and Cereblon (CRBN), a substrate-receptor for the E3-ubiquitin ligase CRL4CRBN, to trigger tau ubiquitination and proteasomal degradation. QC-01-175 effected clearance of tau in frontotemporal dementia (FTD) patient-derived neuronal cell models, with minimal effect on tau from neurons of healthy controls, indicating specificity for disease-relevant forms. QC-01-175 also rescued stress vulnerability in FTD neurons, phenocopying CRISPR-mediated MAPT-knockout. This work demonstrates that aberrant tau in FTD patient-derived neurons is amenable to targeted degradation, representing an important advance for therapeutics.

Data availability

Mass spectrometry global proteomics data is available via the PRIDE archive, under the project accession number PXD012515. Source data files have been provided for Figures 2, 5 and 7.

The following data sets were generated

Article and author information

Author details

  1. M Catarina Silva

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    M Catarina Silva, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5421-6673

  2. Fleur M Ferguson

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Fleur M Ferguson, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4091-7617

  3. Quan Cai

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Quan Cai, is a co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).

  4. Katherine A Donovan

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.

  5. Ghata Nandi

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  6. Debasis Patnaik

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  7. Tinghu Zhang

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.

  8. Hai-Tsang Huang

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4244-2304

  9. Diane E Lucente

    Molecular Neurogenetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  10. Bradford C Dickerson

    MGH Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    Competing interests
    Bradford C Dickerson, is a consultant for Merck, Lilly, Biogen, and Piramal; and receives royalties from Oxford University Press, Cambridge University Press, and Elsevier.

  11. Timothy J Mitchison

    Department of Systems Biology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  12. Eric S Fischer

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    Competing interests
    Eric S Fischer, is a SAB member and equity holder in C4 Therapeutics and a consultant to Novartis, AbbVie, and Pfizer. The Fischer lab receives or has received research funding from Novartis, Astellas and Deerfield.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7337-6306

  13. Nathanael S Gray

    Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, United States
    For correspondence
    nathanael_gray@dfci.harvard.edu
    Competing interests
    Nathanael S Gray, is a founder, science advisory board member (SAB) and equity holder in Gatekeeper, Syros, Petra, C4, B2S and Soltego. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Her2llc, Deerfield and Sanofi. Co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5354-7403

  14. Stephen J Haggarty

    Chemical Neurobiology Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, United States
    For correspondence
    shaggarty@mgh.harvard.edu
    Competing interests
    Stephen J Haggarty, is a member of the SAB and equity holder in Rodin Therapeutics, Psy Therapeutics, and Frequency Therapeutics. His laboratory has received funding from the Tau Consortium, F-Prime Biomedical Research Initiative, AstraZeneca, JW Pharmaceuticals and speaking fees from AstraZeneca, Amgen, Merck. Co-inventor on a patent covering the molecules disclosed in this publication (WO/2019/014429).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7872-168X

Funding

National Institutes of Health (R21NS085487)

  • M Catarina Silva
  • Diane E Lucente
  • Bradford C Dickerson
  • Stephen J Haggarty

Tau Consortium

  • M Catarina Silva
  • Ghata Nandi
  • Debasis Patnaik
  • Stephen J Haggarty

F-Prime Biomedical Research Initiative

  • M Catarina Silva
  • Fleur M Ferguson
  • Ghata Nandi
  • Debasis Patnaik
  • Nathanael S Gray
  • Stephen J Haggarty

National Institutes of Health (R01CA214608)

  • Katherine A Donovan
  • Eric S Fischer

National Institutes of Health (R01CA218278)

  • Katherine A Donovan
  • Eric S Fischer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Eric S Fischer is a Damon Runyon-Rachleff Innovator supported in part by the Damon Runyon Cancer Research Foundation (DRR-50-18).

Reviewing Editor

  1. Benjamin F Cravatt, The Scripps Research Institute, United States

Version history

  1. Received: January 23, 2019
  2. Accepted: March 23, 2019
  3. Accepted Manuscript published: March 25, 2019 (version 1)
  4. Version of Record published: April 5, 2019 (version 2)

Copyright

© 2019, Silva et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 17,473
    Page views
  • 3,247
    Downloads
  • 161
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. M Catarina Silva
  2. Fleur M Ferguson
  3. Quan Cai
  4. Katherine A Donovan
  5. Ghata Nandi
  6. Debasis Patnaik
  7. Tinghu Zhang
  8. Hai-Tsang Huang
  9. Diane E Lucente
  10. Bradford C Dickerson
  11. Timothy J Mitchison
  12. Eric S Fischer
  13. Nathanael S Gray
  14. Stephen J Haggarty
(2019)
Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models
eLife 8:e45457.
https://doi.org/10.7554/eLife.45457

Categories and tags

Research organism

Further reading

    1. Biochemistry and Chemical Biology
    2. Epidemiology and Global Health

    Status and physiological significance of circulating adiponectin in the very old and centenarians: an observational study

    Takashi Sasaki, Yoshinori Nishimoto ... Yasumichi Arai
    Research Article

    Background: High levels of circulating adiponectin are associated with increased insulin sensitivity, low prevalence of diabetes, and low body mass index (BMI); however, high levels of circulating adiponectin are also associated with increased mortality in the 60-70 age group. In this study, we aimed to clarify factors associated with circulating high-molecular-weight (cHMW) adiponectin levels and their association with mortality in the very old (85-89 years old) and centenarians.

    Methods: The study included 812 (women: 84.4%) for centenarians and 1,498 (women: 51.7%) for the very old. The genomic DNA sequence data were obtained by whole genome sequencing or DNA microarray-imputation methods. LASSO and multivariate regression analyses were used to evaluate cHMW adiponectin characteristics and associated factors. All-cause mortality was analyzed in three quantile groups of cHMW adiponectin levels using Cox regression.

    Results: The cHMW adiponectin levels were increased significantly beyond 100 years of age, were negatively associated with diabetes prevalence, and were associated with SNVs in CDH13 (p = 2.21 × 10-22) and ADIPOQ (p = 5.72 × 10-7). Multivariate regression analysis revealed that genetic variants, BMI, and high-density lipoprotein cholesterol (HDLC) were the main factors associated with cHMW adiponectin levels in the very old, whereas the BMI showed no association in centenarians. The hazard ratios for all-cause mortality in the intermediate and high cHMW adiponectin groups in very old men were significantly higher rather than those for all-cause mortality in the low level cHMW adiponectin group, even after adjustment with BMI. In contrast, the hazard ratios for all-cause mortality were significantly higher for high cHMW adiponectin groups in very old women, but were not significant after adjustment with BMI.

    Conclusions: cHMW adiponectin levels increased with age until centenarians, and the contribution of known major factors associated with cHMW adiponectin levels, including BMI and HDLC, varies with age, suggesting that its physiological significance also varies with age in the oldest old.

    Funding: This study was supported by grants from the Ministry of Health, Welfare, and Labour for the Scientific Research Projects for Longevity; a Grant-in-Aid for Scientific Research (No 21590775, 24590898, 15KT0009, 18H03055, 20K20409, 20K07792, 23H03337) from the Japan Society for the Promotion of Science; Keio University Global Research Institute (KGRI), Kanagawa Institute of Industrial Science and Technology (KISTEC), Japan Science and Technology Agency (JST) Research Complex Program 'Tonomachi Research Complex' Wellbeing Research Campus: Creating new values through technological and social innovation (JP15667051), the Program for an Integrated Database of Clinical and Genomic Information from the Japan Agency for Medical Research and Development (No. 16kk0205009h001, 17jm0210051h0001, 19dk0207045h0001); the medical-welfare-food-agriculture collaborative consortium project from the Japan Ministry of Agriculture, Forestry, and Fisheries; and the Biobank Japan Program from the Ministry of Education, Culture, Sports, and Technology.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics

    Vibrio cholerae's ToxRS bile sensing system

    Nina Gubensäk, Theo Sagmeister ... Tea Pavkov-Keller
    Research Article

    The seventh pandemic of the diarrheal cholera disease, which began in 1960, is caused by the Gram-negative bacterium Vibrio cholerae. Its environmental persistence provoking recurring sudden outbreaks is enabled by V. cholerae's rapid adaption to changing environments involving sensory proteins like ToxR and ToxS. Located at the inner membrane, ToxR and ToxS react to environmental stimuli like bile acid, thereby inducing survival strategies e.g. bile resistance and virulence regulation. The presented crystal structure of the sensory domains of ToxR and ToxS in combination with multiple bile acid interaction studies, reveals that a bile binding pocket of ToxS is only properly folded upon binding to ToxR. Our data proposes an interdependent functionality between ToxR transcriptional activity and ToxS sensory function. These findings support the previously suggested link between ToxRS and VtrAC-like co-component systems. Besides VtrAC, ToxRS is now the only experimentally determined structure within this recently defined superfamily, further emphasizing its significance. In-depth analysis of the ToxRS complex reveals its remarkable conservation across various Vibrio species, underlining the significance of conserved residues in the ToxS barrel and the more diverse ToxR sensory domain. Unravelling the intricate mechanisms governing ToxRS's environmental sensing capabilities, provides a promising tool for disruption of this vital interaction, ultimately inhibiting Vibrio's survival and virulence. Our findings hold far-reaching implications for all Vibrio strains that rely on the ToxRS system as a shared sensory cornerstone for adapting to their surroundings.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    A tRNA modification in Mycobacterium tuberculosis facilitates optimal intracellular growth

    Francesca G Tomasi, Satoshi Kimura ... Matthew K Waldor
    Research Article

    Diverse chemical modifications fine-tune the function and metabolism of tRNA. Although tRNA modification is universal in all kingdoms of life, profiles of modifications, their functions, and physiological roles have not been elucidated in most organisms including the human pathogen, Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis. To identify physiologically important modifications, we surveyed the tRNA of Mtb, using tRNA sequencing (tRNA-seq) and genome-mining. Homology searches identified 23 candidate tRNA modifying enzymes that are predicted to create 16 tRNA modifications across all tRNA species. Reverse transcription-derived error signatures in tRNA-seq predicted the sites and presence of nine modifications. Several chemical treatments prior to tRNA-seq expanded the number of predictable modifications. Deletion of Mtb genes encoding two modifying enzymes, TruB and MnmA, eliminated their respective tRNA modifications, validating the presence of modified sites in tRNA species. Furthermore, the absence of mnmA attenuated Mtb growth in macrophages, suggesting that MnmA-dependent tRNA uridine sulfation contributes to Mtb intracellular growth. Our results lay the foundation for unveiling the roles of tRNA modifications in Mtb pathogenesis and developing new therapeutics against tuberculosis.